Oncoimmune Inc
CD200-Fc, a recombinant fusion protein therapeutic that modulates inflammation by combining the extracellular domain of CD200 with the Fc fragment of human IgG
- Sector
- Biotech
- Headquarters
- Columbus, OH
- Latest Form D
- $750K, Apr 2020
- Total capital
- $16M
- Federal grants
- $9.7M
- 13 awards · 2015–2020
- Rank in peer group#303 of 514
- Private capital raised
- $6.3M
- 2 Form D · last Apr 2020
- 79 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 7
- 24 pending · first 2017
- Rank in peer group#48 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · SAC-COVID: An FDA-approved Phase III clinical trial evaluating the safety and therapeutic efficacy of CD24Fc in severe COVID-19 patients$1M
- Federal grantHealth and Human S · Phase II · Cindi Study: A Phase II Clinical Trial to Combine CD24Fc with Ipilimumab and Nivolumab to Decrease Immune Related Adverse Events (irAE)$397K
- Federal grantHealth and Human S · Phase II · First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy$400K
- Private capital raisedForm D · SEC · 2nd filing$750K
- Federal grantHealth and Human S · Phase II · A phase II dose expansion clinical trial testing the efficacy of CD24Fc for the prophylaxis of severe graft vs host disease and leukemia relapse$985K
- Federal grantHealth and Human S · Phase II · A phase II dose expansion clinical trial testing the efficacy of CD24Fc for the prophylaxis of severe graft vs host disease and leukemia relapse$1M
- Federal grantHealth and Human S · Phase I · Evaluation of therapeutic efficacy and safety of novel small RNA target delivery platform in vivo.$313K
- Private capital raisedForm D · SEC · 1st filing$5.5M
Show 7 earlier federal awards
- Federal grantHealth and Human S · Phase II · SAC-COVID: An FDA-approved Phase III clinical trial evaluating the safety and therapeutic efficacy of CD24Fc in severe COVID-19 patients$3M
- Federal grantHealth and Human S · Phase I · A randomized, placebo-controlled, single-blinded clinical trial to assess safety and efficacy of CD24Fc in controlling cardiovascular disease risks of HIV-infected patients$213K
- Federal grantHealth and Human S · Phase II · A randomized, placebo-controlled, single-blinded clinical trial to assess safety and efficacy of CD24Fc in controlling cardiovascular disease risks of HIV-infected patients$213K
- Federal grantHealth and Human S · Phase II · A phase IIA trial for the safety and tolerability of CD24Fc in prophylaxis of graft vs host disease.$4K
- Federal grantHealth and Human S · Phase II · A phase IIA trial for the safety and tolerability of CD24Fc in prophylaxis of graft vs host disease.$983K
- Federal grantHealth and Human S · Phase II · A phase IIA trial for the safety and tolerability of CD24Fc in prophylaxis of graft vs host disease.$1M
- Federal grantHealth and Human S · Phase I · Targeting endogenous sialidases for treatment of endotoxic shock$195K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
19months
from Oncoimmune Inc’s first federal award to its first private round.
- First federal award · Jul 2015
- Health and Human S · $195K
- First Form D · Feb 2017
- $5.5M · 1st Form D
- Awards before first raise
- 1 award
An association in public records, not a cause or a prediction.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#48 · top 9%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Yang LiuResearcherExecutive Officer, DirectorLinked by 6 patents
- Martin DevenportResearcherExecutive OfficerLinked by $2.3M in grants as PI
- Pan ZhengResearcherExecutive OfficerLinked by $7M in grants as PI
- Gary FangerDirectorNamed in SEC Form D filings
- Karen LiuDirectorNamed in SEC Form D filings
- Kun-Liang GuanDirectorNamed in SEC Form D filings
Show all 7 people
- Miao HongDirectorNamed in SEC Form D filings
What it has protected
USPTO · 7 granted of 31- PendingMethods Of Use Of Soluble CD24 For Treating SARS-COV-2 InfectionUSPTOApplication 17798481
- GrantedMethods Of Use Of Soluble CD24 For Treating Lupus NephritisUSPTOUS 11,571,461
- PendingMethods Of Use Of CD24 For The Prevention And Treatment Of Graft Versus Host Disease And MucositisUSPTOApplication 15734961
Show all 31 patent records
- Methods Of Use Of Soluble CD24 For Treating SARS-COV-2 InfectionApr 6, 2023 · Application 17798481Pending
- Methods Of Use Of Soluble CD24 For Treating Lupus NephritisFeb 7, 2023 · US 11,571,461Granted
- Methods Of Use Of CD24 For The Prevention And Treatment Of Graft Versus Host Disease And MucositisJul 29, 2021 · Application 15734961Pending
- Use Of CD24 For Lowering Low-density Lipoprotein Cholesterol LevelsJun 8, 2021 · US 11,026,995Granted
- Use of CD24 Proteins for Treating Leptin-Deficient ConditionsJun 3, 2021 · Application 17067929Pending
- Methods Of Use Of Soluble CD24 For Therapy Of Rheumatoid ArthritisDec 24, 2020 · Application 17009540Pending
- Use of CD24 Proteins for Treating Leptin-Deficient ConditionsOct 13, 2020 · US 10,799,558Granted
- Methods Of Use Of Soluble CD24 For Therapy Of Rheumatoid ArthritisOct 6, 2020 · US 10,793,617Granted
- Uses Of Hypoxia-inducible Factor InhibitorsMay 14, 2020 · Application 16748455Pending
- Uses Of Hypoxia-inducible Factor InhibitorsAug 22, 2019 · Application 16294615Pending
- Use Of CD24 For Lowering Low-density Lipoprotein Cholesterol LevelsAug 6, 2019 · US 10,369,197Granted
- Uses Of Hypoxia-inducible Factor InhibitorsJun 28, 2018 · Application 15839643Pending
- Uses Of Hypoxia-inducible Factor InhibitorsJan 30, 2018 · US 9,877,998Granted
- Methods Of Use Of Soluble CD24 For Therapy Of Rheumatoid ArthritisAug 17, 2017 · Application 15437968Pending
- Uses Of Hypoxia-inducible Factor InhibitorsApr 18, 2017 · US 9,623,070Granted
- Methods Of Use Of Soluble CD24 For Therapy Of Rheumatoid ArthritisSep 5, 2013 · Application 13892705Pending
- Non-blocking ANTI-CTLA4 Antibodies And Uses ThereofApplication 62625662Pending
- Methods Of Use Of Soluble CD24 For Treating Systemic Lupus ErythematosusApplication PCTUS2018021214Pending
- Methods Of Use Of Soluble CD24 For Treating Systemic Lupus ErythematosusApplication 62468049Pending
- Methods Of Use Of Soluble CD24 For The Prevention Of Graft Versus Host DiseaseApplication 62680218Pending
- Methods Of Use Of Soluble CD24 For The Prevention And Treatment Of MucositisApplication 62739719Pending
- Use Of CD24 Proteins For Treating Leptin-deficient ConditionsApplication PCTUS2017016120Pending
- Chimeric And Humanized Anti-human CTLA4 Monoclonal Antibodies And Uses ThereofApplication PCTUS2016066698Pending
- Mutant ANTI-CTLA-4 Antibodies With Improved Immunotherapeutic Effect But Attenuated Adverse EffectsApplication 62754781Pending
- Chimeric And Humanized Anti-human CTLA4 Monoclonal Antibodies And Uses ThereofApplication 62359036Pending
- Use Of CD24 For Lowering Low-density Lipoprotein Cholesterol LevelsApplication PCTUS2016031109Pending
- Compositions of chimeric and humanized anti-human CTLA4 antibodies and uses thereofApplication 62309169Pending
- Use Of CD24 Proteins For Treating Leptin-deficient ConditionsApplication 62290202Pending
- Chimeric And Humanized Anti-human CTLA-4 Antibodies And Uses ThereofApplication 62267735Pending
- Use Of CD24 For Lowering Low-density Lipoprotein Cholesterol LevelsApplication 62158157Pending
- Methods Of Use Of CD24 For The Prevention And Treatment Of Graft Versus Host Disease And MucositisApplication PCTUS2019035200Pending
Related companies, and why
- NUSIRT SCIENCES, INC.Similar federal contract value in Biotech · null in contracts
- CERSCI THERAPEUTICS INCORPORATEDSimilar federal contract value in Biotech · null in contracts
- ARMONICA TECHNOLOGIES, INC.Similar federal contract value in Biotech · null in contracts
- GLOBIN SOLUTIONS INCSimilar federal contract value in Biotech · null in contracts
- ABACUS BIOSCIENCE INCSimilar federal contract value in Biotech · null in contracts
- BIOATLA, LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .